EMA provides these opinions in cooperation with the World Health Organization (WHO).
The legal basis for the EU-M4all procedure is Article 58 of Regulation (EC) No 726/2004.
For more information on the EU-M4all procedure, see Medicines for use outside the European Union.
The pre-submission requirements and evaluation procedure for the EU-M4all procedure are similar to the centralised marketing authorisation procedure.
Applicants may apply in parallel for an EU marketing authorisation under the centralised procedure and an opinion under EU-M4all for their medicine to be used outside the EU. For more information, see Parallel application for EU-M4all opinion and EU marketing authorisation.
The flowchart below contains:
Any stage of the medicinal product lifecycle |
|---|
|
Medicine developers can request scientific advice from EMA at any stage of development although EMA advises seeking scientific advice early, to allow necessary amendments to the development programme. This provides scientific and regulatory guidance on the appropriate tests and studies during the development of a medicine. EU-M4all applicants can also ask questions on the adequacy of pharmacovigilance and risk minimisation measures to be implemented in the countries where they intend to market the medicine. Products confirmed to be eligible for EU-M4all assessment may also be eligible for the PRIME scheme, which supports development of medicines that target an unmet medical need. Experts from WHO or regulatory agencies in target countries may also participate. For more information, see: |
7-18 months before submitting an application |
|---|
|
To find out whether a product can be evaluated under the EU-M4all procedure, applicants should submit the pre-submission request form to article58@ema.europa.eu. The selected scope of request should be: 'Art. 58 scientific opinion application - eligibility request'. In parallel, applicants should send the form via EMA service desk, selecting the tab 'Business Services', category 'Human Regulatory'. The subcategory to be selected is 'Pre-Submission Phase - Human', followed by the sub-option 'Eligibility Request'. If you do not have an EMA account, please create it via the EMA Account Management portal. For further information or guidance about how to create an EMA Account reference the guidance 'Create an EMA Account'.
EMA encourages medicine developers to submit this request as early as possible. EMA liaises with WHO to confirm eligibility. Applicants who apply for an EU marketing authorisation in parallel should submit separate eligibility requests for the two applications. For more information, see:
|
7 months before submitting an application |
|---|
|
Applicants should notify EMA of their intent to submit an application and intended submission date. Applicants should consider the date of submission carefully, taking into account the published submission dates and the guidance below:
To do this, applicants should send the pre-submission request form via EMA service desk, selecting the tab 'Business Services', category 'Human Regulatory'. The subcategory to be selected is 'Pre-Submission Phase - Human', followed by the sub-option 'Letter of Intent Request'. If you do not have an EMA account, please create it via the EMA Account Management portal. For further information or guidance about how to create an EMA Account reference the guidance "Create an EMA Account".
When EMA receives the notification, the CHMP and the Pharmacovigilance Risk Assessment Committee (PRAC) appoints rapporteurs to conduct the scientific assessment. EMA charges a fee for pre-submission requests. For more information on fees to be paid, applicable fee reductions and payment process please refer to the questions & answers document, Annex IV, Section 3 on Fees payable to the European Medicines Agency. If applying for an EU marketing authorisation in parallel, the same CHMP and PRAC rapporteurs will evaluate both applications. WHO-nominated experts and observers from the target country authorities may take part in the evaluation to provide specific local expertise and input. EMA will inform the applicant of the assessors and experts taking part. For more information, see: |
Pre-submission meetings usually take place 6 to 7 months before submitting an application |
|---|
|
Pre-submission meetings are the best opportunity for applicants to obtain procedural and regulatory advice from EMA. Successful pre-submission meetings along with EMA guidance documents should enable applicants to submit applications in line with legal and regulatory requirements. This speeds up the validation process. To request a pre-submission meeting, applicants should send the completed pre-submission interactions form via EMA service desk, selecting the tab 'Business Services', category 'Human Regulatory'. The subcategory to be selected is 'Pre-Submission Phase - Human', followed by the sub-option: 'Pre-Submission Interaction Request'. If you do not have an EMA account, please create it via the EMA Account Management portal. For further information or guidance about how to create an EMA Account reference the guidance 'Create an EMA Account'. EMA has published a question-and-answer document with regulatory and procedural guidance specific to the EU-M4all procedure, which complements EMA's pre-authorisation guidance for the centralised procedure:
|
|
The dossier requirements are mostly the same as for the centralised procedure with a few important differences. For an application under the EU-M4all procedure, the following are not mandatory:
If applicants request an accelerated assessment, they need to justify their request on public health interest grounds in the target countries as opposed to the EU. They should submit their request for accelerated assessment as early as possible and at least 2-3 months before submitting the application. EMA's requirements for pharmacovigilance systems and a risk management plan (RMP) apply to EU-M4all procedures, but the RMP has to be adapted to patients and the health system of the target countries. Some modules of the RMP can be omitted on justified grounds. Applicants who apply for an EU marketing authorisation in parallel should identify the differences between the two dossiers regarding quality, non-clinical and clinical requirements. They should reflect any differences in Modules 1–5 in their submissions (e.g. with a comparative table annexed to Module 1). For more information, see:
|
|
The opinion holder should inform EMA of any changes concerning their medicine following the CHMP opinion. They should consult EMA's Post-authorisation guidance, including on variations and and periodic safety update reports. They should use the following forms, if applicable:
The opinion holder must fulfill the pharmacovigilance requirements agreed with EMA. They should:
Opinion holders should note that EMA's requirements are additional to the pharmacovigilance requirements of the regulatory authorities where the medicine is authorised. In some cases, EMA may request the opinion holder to submit further post-authorisation measures. EMA can also recommend further monitoring and risk-minimisation programmes and conduct a benefit-risk review at any time if new safety information becomes available. For more information, see: |
|
WHO may include the medicine in public health recommendations. WHO provides a streamlined assessment for the prequalification programme for medicines evaluated under the EU-M4all procedure. For more information concerning vaccines, see: Opinion holders can use EMA's opinion to support marketing authorisation applications to regulators in non-EU countries and may benefit from a streamlined procedure. They may also share the CHMP assessment and inspection reports with non-EU regulators in support of their applications. For more information, see:
|